Examples of viable antigens and vaccines
- SPS® technologies increase the thermal stability and protect an H1N1 influenza A vaccine
- The preserved efficacy of the influenza A vaccine was demonstrated in vivo
Cutting-edge stability of dry and liquid formulations in human and animal health. Expertise in inactivated and live attenuated virus vaccines.
Scherließ et al., 2014: Induction of protective immunity against H1N1 influenza A(H1N1)pdm09 with spray-dried and electron-beam sterilised vaccines in non-human primates
Vaccine, 17 2014, Vol.32(19), pp.2231-40 (Link)
The figure shows seroconversion titers of a typical animal model with five different treatment groups, including a PBS control, an inactivated influenza A vaccine in original liquid formulation (H1N1, enveloped RNA virus, Pandemrix®), one spray-dried formulation with mannitol after β-irradiation (E-beam, 25 kGy) and the SPS®-formulated and spray-dried vaccine before and after β-irradiation (E-beam, 25 kGy).
After irradiation of the spray-dried formulation with mannitol (Pandemrix®, SD/β-irradiated), seroconversion completely disappeared.
Seroconversion by the SPS®-formulated vaccine was comparable to the original control (Pandemrix®) and was fully maintained even after irradiation.
The study was done in cooperation with Public Health England.
The figure shows hemagglutination titers for five different groups of a reformulated inactivated influenza A vaccine in comparison to the original liquid formulation which served as a positive control (H1N1, enveloped RNA virus, Pandemrix®).
Lyophilization of the original liquid formulation (Pandemrix®) resulted in a loss of antigen activity.
After lyophilization the SPS®-stabilized and -protected antigen demonstrated titers comparable to the original formulation (dark blue column). Even after accelerated aging at 45°C for 7 days or stressing of the lyophilized SPS®-protected vaccine with 25 kGy or 40 kGy β-irradiation (E-beam) hemagglutination titers were mainly maintained.